Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Docta Complutense
Publication Artículo científico (JournalArticle)

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

  • Martínez Santos, Paula
  • Baldán Martín, Montserrat
  • López, Juan A.
  • Martín Lorenzo, Marta
  • Santiago Hernández, Aránzazu
  • Agudiez, Marta
  • Cabrera Sierra, Martha
  • Calvo, Eva
  • Vázquez, Jesús
  • Ruiz Hurtado, Gema
  • Vivanco, Fernando
  • Ruilope Urioste, Luis Miguel
  • Barderas, María G.
  • Álvarez Llamas, Gloria
Background and aims The predictive value of traditional CV risk calculators is limited. Novel indicators of CVD progression are needed particularly in the young population. The main aim of this study was the identification of a molecular profile with added value to classical CV risk estimation. Methods: Eighty-one subjects (30–50 years) were classified in 3 groups according to their CV risk: healthy subjects; individuals with CV risk factors; and those who had suffered a previous CV event. The urine proteome was quantitatively analyzed and significantly altered proteins were identified between patients' groups, either related to CV risk or established organ damage. Target-MS and ELISA were used for confirmation in independent patients’ cohorts. Systems Biology Analysis (SBA) was carried out to identify functional categories behind CVD. Results: 4309 proteins were identified, 75 of them differentially expressed. ADX, ECP, FETUB, GDF15, GUAD and NOTCH1 compose a fingerprint positively correlating with lifetime risk estimate (LTR QRISK). Best performance ROC curve was obtained when ECP, GDF15 and GUAD were combined (AUC = 0.96). SBA revealed oxidative stress response, dilated cardiomyopathy, signaling by Wnt and proteasome, as main functional processes related to CV risk. Conclusions: A novel urinary protein signature is shown, which correlates with CV risk estimation in young individuals. Pending further confirmation, this six-protein-panel could help in CV risk assessment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, A.
  • Vazquez, I.
  • Cuenca, I.
  • Rosa-Rosa, J.M.|||0000-0003-0806-6453
  • Ariceta, Beñat|||0000-0001-8819-402X
  • Jimenez, C.
  • Fernandez-Mercado, M.
  • Larrayoz, M.J.
  • Gutierrez, N.C.
  • Fernandez-Guijarro, M.
  • Gonzalez-Calle, V.
  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Alegre, Adrian|||0000-0002-2423-822X
  • Escalante, F.
  • de la Rubia, Javier|||0000-0002-8354-768X
  • Teruel, A.I.
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Lopez-Jimenez, Javier|||0000-0002-2969-3002
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Puig, Noemí|||0000-0001-7535-3861
  • Paiva, Bruno|||0000-0003-1977-3815
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Calasanz, M.J.|||0000-0002-0374-3008
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Rios, R.
  • Sureda, Anna|||0000-0002-1238-6970
  • Blanchard, María Jesús
  • Martinez-Martinez, R.
  • Moraleda, J. M.
  • Bargay, Joan|||0000-0002-6739-3916
  • Gironella, Meritxell|||0000-0003-4437-5181
  • Palomera, L.
  • Gonzalez-Montes, Y.
  • Martí, J.M.
  • Krsnik, Isabel|||0000-0002-2912-5072
  • Arguiñano, J.M.
  • González Garcia, Maria Esther|||0000-0002-4238-0377
  • Gonzalez, A.P.
  • Casado Montero, Luis Felipe|||0000-0002-8171-0674
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting.
Repisalud
Publication Artículo científico (JournalArticle)

A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosis

  • Martin-Rojas, Tatiana
  • Mourino-Alvarez, Laura
  • Gil-Dones, Felix
  • de la Cuesta, Fernando
  • Rosello-Lleti, Esther
  • Laborde, Carlos M.
  • Rivera, Miguel
  • Fernando Lopez-Almodovar, Luis
  • Lopez, Juan Antonio
  • Akerstrom, Finn
  • Padial, Luis R.
  • Barderas, Maria G
Background: Calcific aortic stenosis (CAS) is the most common heart valve disease in the elderly, representing an important economic and social burden in developed countries. Currently, there is no way to predict either the onset or progression of CAS, emphasizing the need to identify useful biomarkers for this condition. Methods: We performed a multi-proteomic analysis on different kinds of samples from CAS patients and healthy donors: tissue, secretome and plasma. The results were validated in an independent cohort of subjects by immunohistochemistry, western blotting and selected reaction monitoring. Results: Alpha 1 antichymotrypsin (AACT) abundance was altered in the CAS samples, as confirmed in the validation phase. The significant changes observed in the amounts of this protein strongly suggest that it could be involved in the molecular mechanisms underlying CAS. In addition, our results suggest there is enhanced release of AACT into the extracellular fluids when the disease commences. Conclusions: The significant increase of AACT in CAS patients suggests it fulfils an important role in the physiopathology of this disease. These results permit us to propose that AACT may serve as a potential marker for the diagnosis of CAS, with considerable clinical value.
Repisalud
Publication Artículo científico (JournalArticle)

Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators

  • Baldan-Martin, Montserrat
  • Mourino-Alvarez, Laura
  • Gonzalez-Calero, Laura
  • Moreno-Luna, Rafael
  • Sastre-Oliva, Tamara
  • Ruiz-Hurtado, Gema
  • Segura, Julian
  • Lopez, Juan Antonio
  • Vazquez, Jesus
  • Vivanco, Fernando
  • Alvarez-Llamas, Gloria
  • Ruilope, Luis M
  • de la Cuesta, Fernando
  • Barderas, Maria G
Albuminuria is a risk factor strongly associated with cardiovascular disease, the first cause of death in the general population. It is well established that renin-angiotensin system suppressors prevent the development of new-onset albuminuria in naïf hypertensive patients and diminish its excretion, but we cannot forget the percentage of hypertensive patients who develop de novo albuminuria. Here, we applied multiple proteomic strategy with the purpose to elucidate specific molecular pathways involved in the pathogenesis and provide predictors and chronic organ damage indicators. Briefly, 1143 patients were followed up for a minimum period of 3 years. One hundred and twenty-nine hypertensive patients chronically renin-angiotensin system suppressed were recruited, classified in 3 different groups depending on their albuminuria levels (normoalbuminuria, de novo albuminuria, and sustained albuminuria), and investigated by multiple proteomic strategies. Our strategy allowed us to perform one of the deepest plasma proteomic analysis to date, which has shown 2 proteomic signatures: (1) with predictive value of de novo albuminuria and (2) sustained albuminuria indicator proteins. These proteins are involved in inflammation, immune as well as in the proteasome activation occurring in situations of endoplasmic reticulum stress. Furthermore, these results open the possibility of a future strategy based on anti-immune therapy to treat hypertension which could help to prevent the development of albuminuria and, hence, the progression of kidney damage.
Repisalud
Publication Artículo científico (JournalArticle)

Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension

  • Martin-Lorenzo, Marta
  • Martinez, Paula J
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Minguez, Pablo
  • Santiago-Hernandez, Aranzazu
  • Vazquez, Jesus
  • Segura, Julian
  • Ruiz-Hurtado, Gema
  • Vivanco, Fernando
  • Barderas, Maria G
  • Ruilope, Luis M
  • Alvarez-Llamas, Gloria
Resistant hypertension prevalence is progressively increasing, and prolonged exposure to suboptimal blood pressure control results in higher cardiovascular risk and end-organ damage. Among various antihypertensive agents, spironolactone seems the most effective choice to treat resistant hypertension once triple therapy including a diuretic fails. However success in blood pressure control is not guaranteed, adverse effects are not negligible, and no clinical tools are available to predict patient's response. Complementary to our previous study of resistant hypertension metabolism, here we investigated urinary proteome changes with potential capacity to predict response to spironolactone. Twenty-nine resistant hypertensives were included. A prospective study was conducted and basal urine was collected before spironolactone administration. Patients were classified in responders or nonresponders in terms of blood pressure control. Protein quantitation was performed by liquid chromatography-mass spectrometry; ELISA and target mass spectrometry analysis were performed for confirmation. Among 3310 identified proteins, HP (haptoglobin) and HPR (haptoglobin-related protein) showed the most significant variations, with increased levels in nonresponders compared with responders before drug administration (variation rate, 5.98 and 7.83, respectively). Protein-coordinated responses were also evaluated by functional enrichment analysis, finding oxidative stress, chronic inflammatory response, blood coagulation, complement activation, and regulation of focal adhesions as physiopathological mechanisms in resistant hypertension. In conclusion, protein changes able to predict patients' response to spironolactone in basal urine were here identified for the first time. These data, once further confirmed, will support clinical decisions on patients' management while contributing to optimize the rate of control of resistant hypertensives with spironolactone.
Repisalud
Publication Artículo científico (JournalArticle)

Cardiovascular Risk Stratification Based on Oxidative Stress for Early Detection of Pathology.

  • Corbacho-Alonso, Nerea
  • Baldán-Martín, Montserrat
  • López, Juan Antonio
  • Rodríguez-Sánchez, Elena
  • Martínez, Paula J
  • Mourino-Alvarez, Laura
  • Sastre-Oliva, Tamara
  • Cabrera, Martha
  • Calvo, Eva
  • Padial, Luis R
  • Vázquez, Jesús
  • Vivanco, Fernando
  • Alvarez-Llamas, Gloria
  • Ruiz-Hurtado, Gema
  • Ruilope, Luis M
  • Barderas, Maria G
Current cardiovascular (CV) risk prediction algorithms are able to quantify the individual risk of CV disease. However, CV risk in young adults is underestimated due to the high dependency of age in biomarker-based algorithms. Because oxidative stress is associated with CV disease, we sought to examine CV risk stratification in young adults based on oxidative stress to approach the discovery of new markers for early detection of pathology. Young adults were stratified into (i) healthy controls, (ii) subjects with CV risk factors, and (iii) patients with a reported CV event. Plasma samples were analyzed using FASILOX, a novel approach to interrogate the dynamic thiol redox proteome. We also analyzed irreversible oxidation by targeted searches using the Uniprot database. Irreversible oxidation of cysteine (Cys) residues was greater in patients with reported CV events than in healthy subjects. These results also indicate that oxidation is progressive. Moreover, we found that glutathione reductase and glutaredoxin 1 proteins are differentially expressed between groups and are proteins involved in antioxidant response, which is in line with the impaired redox homeostasis in CV disease. This study, for the first time, describes the oxidative stress (reversible and irreversible Cys oxidation) implication in human plasma according to CV risk stratification. The identification of redox targets and the quantification of protein and oxidative changes might help to better understand the role of oxidative stress in CV disease, and aid stratification for CV events beyond traditional prognostic and diagnostic markers. . 35, 602-617.
Repisalud
Publication Artículo científico (JournalArticle)

Identification of six cardiovascular risk biomarkers in the young population: A promising tool for early prevention

  • Martínez, Paula J
  • Baldan-Martin, Montserrat
  • Lopez, Juan Antonio
  • Martín-Lorenzo, Marta
  • Santiago-Hernández, Aránzazu
  • Agudiez, Marta
  • Cabrera, Martha
  • Calvo, Eva
  • Vazquez, Jesus
  • Ruiz-Hurtado, Gema
  • Vivanco, Fernando
  • Ruilope, Luis M
  • Barderas, Maria G
  • Alvarez-Llamas, Gloria
BACKGROUND AND AIMS: The predictive value of traditional CV risk calculators is limited. Novel indicators of CVD progression are needed particularly in the young population. The main aim of this study was the identification of a molecular profile with added value to classical CV risk estimation. METHODS: Eighty-one subjects (30-50 years) were classified in 3 groups according to their CV risk: healthy subjects; individuals with CV risk factors; and those who had suffered a previous CV event. The urine proteome was quantitatively analyzed and significantly altered proteins were identified between patients' groups, either related to CV risk or established organ damage. Target-MS and ELISA were used for confirmation in independent patients' cohorts. Systems Biology Analysis (SBA) was carried out to identify functional categories behind CVD. RESULTS: 4309 proteins were identified, 75 of them differentially expressed. ADX, ECP, FETUB, GDF15, GUAD and NOTCH1 compose a fingerprint positively correlating with lifetime risk estimate (LTR QRISK). Best performance ROC curve was obtained when ECP, GDF15 and GUAD were combined (AUC = 0.96). SBA revealed oxidative stress response, dilated cardiomyopathy, signaling by Wnt and proteasome, as main functional processes related to CV risk. CONCLUSIONS: A novel urinary protein signature is shown, which correlates with CV risk estimation in young individuals. Pending further confirmation, this six-protein-panel could help in CV risk assessment.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

  • Medina-Herrera, Alejandro
  • Vázquez Urio, Iria
  • Cuenca, Isabel
  • Rosa-Rosa, Juan Manuel
  • Ariceta, Beñat
  • Jiménez, Cristina
  • Fernández-Mercado, Marta
  • Larráyoz, María José
  • Gutiérrez, Norma C.
  • Fernández-Guijarro, M.
  • González-Calle, Verónica
  • Rodríguez-Otero, Paula
  • Oriol, Albert
  • Rosiñol, Laura
  • Alegre, Adrián
  • Escalante, Fernando
  • Rubia, Javier de la
  • Teruel, A. I.
  • Arriba, Felipe de
  • Hernández, Miguel-Teodoro
  • López-Jiménez, Javier
  • Ocio, Enrique María
  • Puig, Noemí
  • Paiva, Bruno David Lourenço
  • Lahuerta, Juan-José
  • Bladé, Joan
  • San-Miguel, Jesús F.
  • Mateos, María-Victoria
  • Martínez-López, Joaquín
  • Calasanz, María José
  • García-Sanz, Ramón
  • GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group
Smoldering multiple myeloma (SMM) precedes multiple myeloma (MM). The risk of progression of SMM patients is not uniform, thus different progression-risk models have been developed, although they are mainly based on clinical parameters. Recently, genomic predictors of progression have been defined for untreated SMM. However, the usefulness of such markers in the context of clinical trials evaluating upfront treatment in high-risk SMM (HR SMM) has not been explored yet, precluding the identification of baseline genomic alterations leading to drug resistance. For this reason, we carried out next-generation sequencing and fluorescent in-situ hybridization studies on 57 HR and ultra-high risk (UHR) SMM patients treated in the phase II GEM-CESAR clinical trial (NCT02415413). DIS3, FAM46C, and FGFR3 mutations, as well as t(4;14) and 1q alterations, were enriched in HR SMM. TRAF3 mutations were specifically associated with UHR SMM but identified cases with improved outcomes. Importantly, novel potential predictors of treatment resistance were identified: NRAS mutations and the co-occurrence of t(4;14) plus FGFR3 mutations were associated with an increased risk of biological progression. In conclusion, we have carried out for the first time a molecular characterization of HR SMM patients treated with an intensive regimen, identifying genomic predictors of poor outcomes in this setting., This work was partially supported by Amgen, the Asociación Española Contra el Cáncer (AECC, PROYE20047GUTI), the Instituto de Salud Carlos III (ISCIII, PI21/01917 and PMP21/00015), the Centro de Investigación Biomédica en Red (CIBERONC CB16/12/00233, CB16/12/00284, CB16/12/00369 and CB16/12/00489), the Cancer Research UK (C355/A26819) and FC AECC and AIRC under the Accelerator Award Program, and 'Una manera de hacer Europa' (Innocampus; CEI-2010-1-0010). CJ was supported by the ISCIII (CD19/00030), AM-H by the European Social Fund through the IBSAL, the ISCIII (FI19/00320), the International Myeloma Society and the Spanish Society of Hematology (co-funded by Janssen). All Spanish funding is co-sponsored by the European Union FEDER program. MVM is the president of the Spanish Society of Hematology. JJL is the president of the GEM-PETHEMA group.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Pancreas fat content, insulin homeostasis and circulating endothelial microparticles in male essential hypertensive patients

  • Alfaro Lara, V.
  • Muñoz-Hernández, Rocío
  • Giménez-Miranda, L.
  • Beltrán-Romero, Luis Matías
  • Castell, Francisco J.
  • Stiefel, Pablo
© 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made., The pancreas fat content has been poorly investigated in essential hypertension. The authors aim to relate pancreas and liver fat content with parameters measuring insulin resistance, beta-cell function and also with markers of endothelial dysfunction and platelet or endothelial cell destruction. The authors studied a group of 40 male hypertensive patients with well-controlled blood pressure, maintaining a stable weight, and having not changed their medication during the last year. Pancreas fat content was correlated with HOMA-IR (r = .616, p < .001), HOMA-S (r = −.439, p < .005), beta cell function parameter (r = .457, p < .005), and QUICKI (r = .412, p < .01), whereas liver fat was not patients in the highest quartile of pancreas fat content had more circulating endothelial microparticles than patients in the other quartiles (median 129 [94.3–200] vs. 60.9 [49.4–88.8], p = .002). However, patients in the highest quartile of the pancreas fat content distribution did not differ from the lowest in hyperemic response after ischemia nor circulating platelet microparticles count. Liver fat content was not related to any of the parameters studied. In a multivariate stepwise binary logistic regression analysis (Wald Method) circulating endothelial microparticles remain significantly associated with pancreas fat content after adjusting for confounding factors, such as tobacco, diabetes mellitus, hypercholesterolemia, or metabolic syndrome. Our results reflect that in essential hypertension, pancreas fat content is superior to liver fat to study beta-cell functionality and insulin resistance. Moreover, the authors described for the first time that pancreas fat content is related to endothelial cell destruction. Further studies are needed to confirm this point., This work was supported by Instituto de Salud Carlos III to Pablo Stiefel (PI13/01917). Instituto de Salud Carlos III. Ministerio de Ciencia e Innovación. Spain., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells

  • Royo, Maria
  • Sandoval Moreno, Sebastian
  • Gabaldon Dominguez, Alejandra
  • Solé, Cristina
  • Moline, Teresa
  • Cortes Hernandez, Josefina
B cell; Lupus nephritis, Célula B; Nefritis lúpica, Cèl·lules B; Nefritis lúpica, Despite conventional therapy, lupus nephritis (LN) remains a significant contributor to short- and long-term morbidity and mortality. B cell abnormalities and the production of autoantibodies against nuclear complexes like anti-dsDNA are recognised as key players in the pathogenesis of LN. To address the challenges of chronic immunosuppression associated with current therapies, we have engineered T cells to express chimeric autoantibody receptors (DNA-CAART) for the precise targeting of B cells expressing anti-dsDNA autoantibodies. T cells from LN patients were transduced using six different CAAR vectors based on their antigen specificity, including alpha-actinin, histone-1, heparan sulphate, or C1q. The cytotoxicity, cytokine production, and cell–cell contact of DNA-CAART were thoroughly investigated in co-culture experiments with B cells isolated from patients, both with and without anti-dsDNA positivity. The therapeutic effects were further evaluated using an in vitro immune kidney LN organoid. Among the six proposed DNA-CAART, DNA4 and DNA6 demonstrated superior selectively cytotoxic activity against anti-dsDNA+ B cells. Notably, DNA4-CAART exhibited improvements in organoid morphology, apoptosis, and the inflammatory process in the presence of IFNα-stimulated anti-dsDNA+ B cells. Based on these findings, DNA4-CAART emerge as promising candidates for modulating autoimmunity and represent a novel approach for the treatment of LN., This research was funded by Instituto de Salud Carlos III, ISCIII, grant number PI18/01917.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells

  • Royo, Maria
  • Sandoval Moreno, Sebastian
  • Gabaldon Dominguez, Alejandra
  • Solé, Cristina
  • Moline, Teresa
  • Cortes Hernandez, Josefina
B cell; Lupus nephritis, Célula B; Nefritis lúpica, Cèl·lules B; Nefritis lúpica, Despite conventional therapy, lupus nephritis (LN) remains a significant contributor to short- and long-term morbidity and mortality. B cell abnormalities and the production of autoantibodies against nuclear complexes like anti-dsDNA are recognised as key players in the pathogenesis of LN. To address the challenges of chronic immunosuppression associated with current therapies, we have engineered T cells to express chimeric autoantibody receptors (DNA-CAART) for the precise targeting of B cells expressing anti-dsDNA autoantibodies. T cells from LN patients were transduced using six different CAAR vectors based on their antigen specificity, including alpha-actinin, histone-1, heparan sulphate, or C1q. The cytotoxicity, cytokine production, and cell–cell contact of DNA-CAART were thoroughly investigated in co-culture experiments with B cells isolated from patients, both with and without anti-dsDNA positivity. The therapeutic effects were further evaluated using an in vitro immune kidney LN organoid. Among the six proposed DNA-CAART, DNA4 and DNA6 demonstrated superior selectively cytotoxic activity against anti-dsDNA+ B cells. Notably, DNA4-CAART exhibited improvements in organoid morphology, apoptosis, and the inflammatory process in the presence of IFNα-stimulated anti-dsDNA+ B cells. Based on these findings, DNA4-CAART emerge as promising candidates for modulating autoimmunity and represent a novel approach for the treatment of LN., This research was funded by Instituto de Salud Carlos III, ISCIII, grant number PI18/01917.